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Role of endothelin-1 and thromboxane A2 in renal vasoconstric- through a variety of mechanisms [1–3]. In addition, throm-
tion induced by angiotensin II in diabetes and hypertension. boxane A2 (TXA2) and endothelin-1 (ET-1) exert vascu-
Background. Interactions among angiotensin II (Ang II), lar renal and systemic actions similar to those of Ang II,endothelin-1 (ET-1) and thromboxane A2 (TXA2) may play and may play a role in the renal alterations associatedan important role in the regulation of renal function. The pres-
with hypertension and diabetes [4–6]. Altered vascularent study investigated the participation of TXA2 and ET-1 in
the increase in renal vascular resistances (RVR) induced by reactivity as well as increased production of different
Ang II, as well as the consequences of diabetes, hypertension, vasoconstrictors including serotonin, noradrenalin, Ang II,
and the combination of both on this response. ET-1 and TXA2, have been reported in experimentalMethods. Isolated kidneys from male normoglycemic or
models of diabetes and hypertension, yielding a varietystreptozotocin-induced diabetic Wistar-Kyoto rats (WKY) and
of results [4–9]. Several studies reported interactionsspontaneously hypertensive rats (SHR) were used. The in-
crease in perfusion pressure (PP) produced by Ang II was studied among Ang II, ET-1 and TXA2 that could be important in
in the absence or presence of the TXA2 receptor antagonist, the regulation of renal function [7, 9–11]. We previously
ifetroban, or the ETA/ETB receptor antagonist, PD145065. observed that the angiotensin II type 1 (AT1) receptor
Results. Systolic arterial pressure (SAP) was higher in SHR
antagonist losartan reduced constrictor responses to ET-1than in WKY, but diabetic rats (D) from each strain showed
and a TXA2 analog in aortic rings from spontaneouslylower SAP values than their respective non-diabetic rats. Basal
hypertensive rats (SHR), suggesting a role for Ang II asrenal PP was higher in WKY and SHR than in WKY-D and
SHR-D. Increases in renal PP produced by Ang II were compa- a mediator of the constrictor response to these endothe-
rable in the kidneys from all groups. Either ifetroban or lium-derived contracting factors [12]. In addition, other
PD145065 reduced the maximal Ang II response in all animals. studies suggested that TXA2 and ET-1 inhibition couldThe maximal inhibitory effect of ifetroban was higher (P 
affect the vascular actions of Ang II [7, 9, 11]. Thus, the0.05) in WKY than in the other groups. However, the maximal
aim of the present study was to investigate the possibleinhibitory effect of PD145065 was lower in SHR than in the
other groups. mediating role of TXA2 and ET-1 in the increase in renal
Conclusion. This study supports a role for ET-1 and TXA2 vascular resistance (RVR) induced by Ang II, as well
as mediators of the increase in renal vascular resistance pro- as the consequences of diabetes, hypertension, and the
duced by Ang II. These results indicate that the participation combination of both on this response. For this purposeof ET-1 in the renal vasoconstriction produced by Ang II was
we studied renal constrictor responses to Ang II in iso-reduced under hypertensive conditions, and that of TXA2 was
lated kidneys from normal, diabetic, hypertensive andreduced by both diabetes and hypertension.
hypertensive-diabetic rats in the absence and presence
of the TXA2 receptor antagonist, ifetroban and the ETA/
ETB receptor antagonist PD145065.Angiotensin II (Ang II) plays a key role in the regula-
tion of renal function and arterial pressure and has been
widely shown to participate in the renal functional and METHODS
structural complications of diabetes and hypertension
Male adult (28-week-old) Wistar-Kyoto rats (WKY;
N 40) and spontaneously hypertensive rats (SHR; N
40; Charles River, Barcelona, Spain) maintained underKey words: kidney, hypertension, diabetes, renal vascular resistance,
arterial pressure, arterial pressure, chronic renal disease. controlled light and temperature conditions were used
in the study. Eight weeks before the experiment, diabetes 2002 by the International Society of Nephrology
S-2
Cediel et al: Renal interactions among Ang II, TXA2 and ET-1 S-3
Table 1. Systolic arterial pressure (SAP), plasma glucose (PG), body weight (BW), kidney relative weight (KW/BW) in WKY, SHR,
diabetic WKY (WKY-D) and diabetic SHR (SHR-D)
WKY SHR WKY-D SHR-D
SAP mm Hg 135.01.6 196.74.9a 115.82.5a 153.76.6b
PG mmol/L 9.00.6 8.60.6a 26.21.1a 27.81.4b
BW g 373.72.9 412.85.7a 245.59.0a 194.211.7b
KW/BW mg/100 g BW 377.88.1 363.27.0 648.522.5a 686.825.0b
aP  0.05 WKY
bP  0.05 vs. SHR
was induced by an intraperitoneal injection of streptozo- distilled water and diluted to the desired concentration
tocin (65 mg/kg; STZ) prepared in citrate buffer in a with Kreb’s solution immediately before the experiment.
portion of the animals from both strains. Animals had Results are expressed as means  SEM of at least eight
free access to food (A.04; Panlab, Barcelona, Spain) and experiments. Dose-response curves were compared by
tap water. Body weight and plasma glucose concentration multivariate analysis of variance for repeated measures
were measured weekly. Systolic arterial pressure (SAP) (MANOVA) using the SPSS program (Statoft Inc., Tulsa,
was estimated by a tail-cuff plethysmograph (Narco Bio- OK, USA). All other data were analyzed using a one-way
Systems, Houston, TX, USA) as previously described [13]. analysis of variance (ANOVA), followed by the Newman-
Eight weeks after the streptozotozin injection, animals Keuls test if differences were noted. The null hypothesis
were anesthetized with sodium pentobarbital (50 mg/kg was rejected when the P value was less than 0.05.
IP); the aorta was exposed by midline laparotomy and
cannulated below the left kidney. Left kidneys were per-
RESULTSfused, renal veins and ureters were cut, and then were
placed in a water-jacketed chamber maintained at 37C As shown in Table 1, systolic arterial pressure levels
and perfused at constant flow (4 mL/min) without recir- were higher (P 0.05) in SHR than in WKY, and glucose
culation by an infusion pump (Harvard Apparatus, South plasma levels were higher (P  0.05) in diabetic than
Natick, MA, USA) with oxygenated (95% O2/5% CO2) in normoglycemic rats. Diabetic rats from each strain
Krebs’s bicarbonate solution of the following composi- showed lower (P  0.05) SAP than respective non-dia-
tion (mmol/L): NaCl 118.5, KCl 4.7, CaCl2 2.8, KH2PO4 betics. Body weight was higher (P  0.05) in SHR than
1.1, NaHCO3 25.0 and glucose 11.1, at 37C. Perfusion in WKY (Table 1). Diabetes was associated with a reduc-
pressure (PP) was continuously monitored using a pres- tion of body weight in both strains, although this effect
sure transducer (model P23XL; Spectromed, Cleveland, was more marked in SHR. Kidney relative wet weight
OH, USA) and recorded on a polygraph (Model 7E; Grass was higher (P  0.05) in the diabetic than in normogly-
Instruments, Quincy, MA, USA). All experimental pro- cemic groups (Table 1).
cedures were approved by the Animal Care and Use Basal PP was higher (P  0.05) in WKY (85.4  5.7
Committee from Complutense University, according to mm Hg) and SHR (89.3  5.8 mm Hg) than in diabetic
the guidelines for ethical care of experimental animals WKY rats (WKY-D; 67.4  3.6 mm Hg) and SHR-D
of the European Union. (71.6  7.5 mm Hg). Increases in PP produced by KCl
After a 30 to 45 minute equilibration period, the kid-
were comparable in kidneys from all groups (data not
neys were contracted with 60 mmol/L KCl and these re-
shown). Similarly, dose-dependent increases in PP pro-sponses were used as references to express contractions
duced by Ang II were comparable in kidneys from allto Ang II. Dose-related contracting responses induced by
groups (Fig. 1). The presence of either ifetroban or108 to 105 mol/L Ang II were evaluated in all animals.
PD145065 in perfusion media reduced (P  0.05) theAfterwards, a dose-response curve to 105 mol/L Ang II
Ang II maximal response in all groups in a differentialin presence of the TXA2 receptor antagonist, 108 to 104
manner (Fig. 2 and 3). This inhibitory effect occurred atmol/L ifetroban, or the ETA/ETB receptor antagonist,
lower concentrations of ifetroban in WKY and SHR than108 to 104 mol/L PD145065, were assayed in kidneys
in WKY-D and SHR-D (Fig. 2). In contrast, the inhibi-from each group. Since the perfusion rate was constant
tory effect occurred at lower concentrations of PD145 inthroughout the experimental period, variations of perfu-
WKY-D and SHR-D than in WKY and SHR (Fig. 3).sion pressure (PP) were indicative of changes in renal
The maximal inhibitory effect of ifetroban was highervascular resistance (RVR). Changes in renal PP were
(P  0.05) in WKY than in the other groups (Table 2).calculated by subtracting the value of PP obtained just
However, the maximal inhibitory effect of PD145065before the Ang II injection from the value of PP mea-
was lower (P  0.05) in SHR than in the other groups.sured at the time of maximal effect. All drugs and chemi-
Diabetes increased the maximal inhibitory effect ofcals were purchased from Sigma Chemical Co. (St. Louis,
MO, USA). Stock solutions of drugs were prepared in PD145 in both strains (Table 2).
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Fig. 1. Concentration-dependent increases in
perfusion pressure produced by angiotensin
II (Ang II) in isolated kidneys from Wistar-
Kyoto rats (WKY; A ), diabetic WKY (B ),
spontaneous hypertensive rats (SHR; C ), and
diabetic SHR (D ).
Fig. 2. Concentration-dependent reductions
produced by ifetroban on the increase in per-
fusion pressure produced by 105 mol/L angio-
tensin II in isolated kidneys from WKY (A ),
diabetic WKY (B ), SHR (C ) and diabetic
SHR (D ).
DISCUSSION loss in these animals [14, 15]. Furthermore, consistent
with previous studies, diabetes was associated with lowerThe STZ diabetic rat model used in this study displays
SAP levels in both normotensive and hypertensive rats,many of the features of human diabetes, including hyper-
which appears to be due to a defective regulation ofglycemia, weight loss and renal hypertrophy [14]. The
vascular tone [16, 17]. Moreover, basal RVR values wereresults support the concept that SHR exhibit a higher
reduced in both diabetic strains, suggesting that diabetessusceptibility to alterations produced by STZ-induced
diabetes than WKY, as suggested by the greater weight is associated with a reduced renal vascular tone [17, 18].
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Fig. 3. Concentration-dependent reductions
produced by PD145065 on the increase in per-
fusion pressure produced by angiotensin II
(105 mol/L) in isolated kidneys from WKY
(A ), diabetic WKY (B ), SHR (C ) and dia-
betic SHR (D ).
Table 2. Maximal inhibitory effect (%) produced by either trast with those found in young SHR, where the renal
ifretroban or PD145065 on increases in perfusion pressure
response to Ang II was higher than in normotensive ratsinduced by 105 mol/L angiotensin II
[17, 19, 20, 22]. The enhanced renal responsiveness to
WKY SHR WKY-D SHR-D Ang II and other vasoconstrictors has been proposed
Ifetroban 53.4 38.3 27.46 39.29 to be an important determinant of the development of
PD145065 52.9 31.7 69.92 56.25
hypertension in SHR. However, it appears that once
hypertension is established this elevated response is nor-
malized. In addition, STZ-induced diabetes did not affect
the increased RVR produced by Ang II either in theIn contrast, basal RVR values were comparable in both
WKY or SHR. Unchanged or diminished renal constric-WKY and SHR, indicating that renal vascular tone is
tor responses to Ang II agents have been reported in dia-not altered in established hypertension as was reported
betic normotensive and hypertensive rats [17, 18, 23–25].previously [17, 19, 20]. Several mechanisms could con-
The different results appear to depend on the experimen-tribute to alterations of vascular tone in diabetic rats.
tal conditions, age of animals and evolution of diabetes.Increased production of vasodilatory prostanoids, down-
Our current study indicates that both TXA2 and ET-1regulation of receptors to systemic vasoconstrictor agents
partially mediate renal vasoconstriction produced byor the impairment of smooth muscle contractile machin-
Ang II in all of the rat groups, as suggested by the reducedery produced by prolonged hyperglycemia could have
contracting responses observed in presence of ifetrobancontributed to the observed reduction of SAP in diabetic
or PD145065. This mediation appears to depend on therats. It has been proposed that abnormal activation of
stimulatory effect of Ang II on TXA2 and ET-1 produc-protein kinase C (PKC) may underlie the marked vasodi-
tion [26–30]. Furthermore, it has been proposed thatlation status and defective vasoconstrictor response char-
these two endothelium-derived contracting factors alsoacterizing diabetes mellitus [21].
act as amplifiers of the constrictor response to Ang IIThe increase in renal PP produced by Ang II was
[31]. In addition, common intracellular signaling path-comparable in all groups studied, indicating that under
ways involved in contraction of arterial smooth musclethe present experimental conditions, neither hyperten-
cells, such as PKC, might be important mechanisms un-sion nor diabetes or the combination of both affected
derlying the participation of TXA2 and ET-1 in Ang IIrenal vascular response to Ang II. These results are in
agreement with those reported for adult SHR and con- renal vasoconstriction [32]. Relative participation of
Cediel et al: Renal interactions among Ang II, TXA2 and ET-1S-6
TXA2 and ET-1 in the increase in RVR produced by REFERENCES
Ang II was differentially affected by hypertension and 1. Parving HH: Hypertension and diabetes: the scope of the problem.
Blood Press (Suppl 2):25–31, 2001diabetes. Participation of TXA2 was maximal in WKY
2. Ma L, Fogo AB: Role of angiotensin II in glomerular injury. Seminand was diminished by hypertension and diabetes, al-
Nephrol 21:544–553, 2001
though no additive effect of both entities was observed. 3. Unger T: The role of the renin-angiotensin system in the develop-
ment of cardiovascular disease. Am J Cardiol 89:3–9, 2002The reduction in the participation of TXA2 in the Ang II
4. Nasjletti A, Arthur C: Corcoran Memorial Lecture. The role ofresponse could be due to a diminished ability of Ang II
eicosanoids in angiotensin-dependent hypertension. Hypertension
to stimulate TXA2. However, several studies suggested 31:194–200, 1998
5. Wolf G, Ziyadeh FN: Molecular mechanisms of diabetic renalthat during development of different types of experimen-
hypertrophy. Kidney Int 56:393–405, 1999tal hypertension, arachidonic acid vasoconstrictor deriv-
6. Schiffrin EL: Role of endothelin-1 in hypertension and vascular
atives are increased and mediates the effects of Ang II. disease. Am J Hypertens 14(Suppl):83S–89S, 2001
7. Mistry M, Nasjletti A: Contrasting effect of thromboxane syn-The participation of TXA2 in the regulation of RVR in
thase inhibitors and a thromboxane receptor antagonist on thediabetes has yielded varied results [33, 34]. While several
development of angiotensin II-salt-induced hypertension in rats.
studies proposed an important role for TXA2 in the renal J Pharmacol Exp Ther 253:90–94, 1990
8. Uriu K, Kaizu K, Hashimoto O, et al: Acute and chronic effectsfunctional and structural alterations produced by diabetes,
of thromboxane A2 inhibition on the renal hemodynamics in strep-others reported a decreased responsiveness of vascular seg-
tozotocin-induced diabetic rats. Kidney Int 45:794–802, 1994
ments to TXA2 [35]. The differences among the studies 9. d’Uscio LV, Moreau P, Shaw S, et al: Effects of chronic ETA-
receptor blockade in angiotensin II-induced hypertension. Hyper-seem to be due to the different experimental conditions.
tension 29:435–441, 1997Relative participation of ET-1 in Ang II renal vasocon- 10. Chatziantoniou C, Daniels FH, Arendhorst WJ: Exaggerated
striction was reduced in SHR, suggesting (as proposed renal vascular reactivity to angiotensin and thromboxane in young
genetically hypertensive rats. Am J Physiol 259:F372–F382, 1990for TXA2) that hypertension alters the ability of Ang II
11. Wilcox CS, Welch WJ: Thromboxane mediation of the pressorto stimulate ET-1. Thus, it could be postulated that the response to infused angiotensin II. Am J Hypertens 3:242–249, 1990
participation of ET-1 is less important as a mediator of 12. Maeso R, Rodrigo E, Mun˜oz-Gracı´a R, et al: Losartan reduces
constrictor responses to endothelin-1 and the thromboxane A2Ang II renal vasoconstriction in established hyperten-
analogue in aortic rings from spontaneously hypertensive rats: rolesion. In fact, it has been shown that ET-1 participates of nitric oxide. J Hypertens 12(Pt 2):1677–1684, 1997
only in the initial phase of Ang II-induced hypertension 13. Maeso R, Rodrigo E, Mun˜oz-Garcı´a R, et al: Chronic treatment
with losartan ameliorates vascular dysfunction induced by aging[36]. In contrast, diabetes enhanced the participation of
in spontaneously hypertensive rats. J Hypertens 16:665–672, 1998ET-1 in the renal vasoconstriction produced by Ang II. 14. Cooper ME, Allen TJ, Jerums G, Doyle AE: Accelerated pro-
Moreover, it appears that diabetes was able to counteract gression of diabetic nephropathy in the spontaneously hypertensive
streptozotozin diabetic rat. Clin Exp Phramacol Physiol 13:655–the reduction of the participation of ET-1 in the Ang II
661, 1986vasoconstriction produced by hypertension, as demon- 15. Somani P, Singh HP, Saini RK, Rabinovitch A: Streptozotozin-
strated by the higher inhibitory effect of PD145065 in induced diabetes in the spontaneously hypertensive rat. Metabo-
lism 28:1075–1080, 1979diabetic SHR when compared with normoglycemic SHR.
16. Yamamoto J: Blood pressure and metabolic effects of streptozo-Supporting the importance of ET-1 in diabetes are stud- tozin in Wistar Kyoto and spontaneously hypertensive rats. Clin
ies showing increased ET-1 gene expression and sensitiv- Exp Hypertens 10:1065–1072, 1988
17. Beenen OHM, Mathy MJ, Pfaffendorf M, van Zwieten PA:ity to ET-1 in isolated kidneys of STZ rats [37, 38].
Vascular responsiveness in isolated perfused kidneys of diabeticFinally, the different impacts of hypertension and diabe- hypertensive rats. J Hypertens 14:1125–1130, 1996
tes on the participation of ET-1 and TXA2 in the increase 18. Farina NK, Hodgson WC, Widdop RE: Vascular reactivity to
angiotensin II in blood-perfused kidneys of hypertensive diabeticof RVR produced by Ang II could rely on the differences
rats. Eur J Pharmacol 310:185–191, 1996in the mechanisms responsible for the alterations associ- 19. Fink GD, Brody MJ: Renal vascular resistance and reactivity in
ated with these two entities at a vascular level. the spontaneously hypertensive rat. Am J Physiol 237:F128–F132,
1979In conclusion, the present study further supports the
20. Kost CK Jr, Kerzer WA, Li P, Jackson EK: Vascular reactivityimportant role of ET-1 and TXA2 as mediators in the to angiotensin II is selectively enhanced in the kidneys of spontane-
increase in RVR produced by Ang II. Hypertension and ously hypertensive rats. J Pharmacol Exp Ther 269:82–88, 1994
21. Awazu M, Parker RE, Harvie BR, et al: Down-regulation ofdiabetes had different consequences on this mediation
endothelin-1 receptors by protein kinase C in streptozotocin dia-and did not show any additive effect. betic rats. J Cardiovasc Pharmacol 17(Suppl 7):S500–S502, 1991
22. Vyas SJ, Jackson EK: Angiotensin II: Enhanced renal respon-
siveness in young genetically hypertensive rats. J Pharmacol ExpACKNOWLEDGMENTS
Ther 273:768–777, 1995
This work was supported by grants from Comisio´n Interministerial 23. Inman SR, Porter JP, Fleming JT: Reduced renal microvascular
de Ciencia y Tecnologı´a (SAF 2001-1864) and from Fondo de Investi- reactivity to angiotensin II in diabetic rats. Microcirculation 1:137–
gaciones Sanitarias (FIS 01/0088-02). We thank Mrs. Blanca Martı´nez 145, 1994
and Mr. Antonio Carmona for their technical assistance. 24. Mayhan WG: Constrictor responses of the rat basilar artery during
diabetes mellitus. Brain Res 783:326–331, 1998
25. Crijns FR, Struijker HA, Wolffenbuttel BH: Arteriolar reactiv-Reprint requests to Dr. V. Lahera, Departamento de Fisiologı´a, Fa-
cultad de Medicina, Universidad Complutense, Madrid 28040, Spain. ity in conscious diabetic rats: Influence of aminoguanidine treat-
ment. Diabetes 47:918–923, 1998E-mail: vlahera@med.ucm.es
Cediel et al: Renal interactions among Ang II, TXA2 and ET-1 S-7
26. Shibouta Y, Inada Y, Terashita Z, et al: Angiotensin-II-stimu- 32. Ruan X, Arendhorst WJ: Role of protein kinase C in angiotensin
II-induced renal vasoconstriction in genetically hypertensive rats.lated release of thromboxane A2 and prostacyclin (PGI2) in iso-
Am J Physiol 270(Pt 2):F945–F952, 1996lated, perfused kidneys of spontaneously hypertensive rats. Bio-
33. Wilcox CS, Welch WJ: Angiotensin II and thromboxane in thechem Pharmacol 28:3601–3609, 1979
regulation of blood pressure and renal function. Kidney Int27. Lin L, Nasjletti A: Role of endothelium-derived prostanoid in
38(Suppl 30):S81–S83, 1990angiotensin-induced vasoconstriction. Hypertension 18:158–164,
34. Cruz BV, Escalante B: Renal vascular interaction of angiotensin1991
II and prostaglandins in renovascular hypertension. J Cardiovasc28. Dumont Y, D’Amours M, Lebel M, Lariviere R: Blood pressure-
Pharmacol 34:21–27, 1999independent effect of angiotensin AT1 receptor blockade on renal
35. Morinelli TA, Tempel Ge, Jaffa AA, et al: Thromboxane A2/endothelin-1 production in hypertensive uremic rats. J Hypertens
prostaglandin H2 receptors in streptozotocin-induced diabetes: Ef-19:1479–1487, 2001
fects of insulin therapy in the rat. Prostaglandins 45:427–38, 199329. Boemke W, Hocher B, Schleyer N, et al: Hemodynamic, renal 36. Ficai S, Herizi A, Mimram A, Jover B: Endothelin blockade in
and endocrine responses to acute ET (A) blockade at different angiotensin II hypertension: Prevention and treatment studies in
angiotensin II plasma levels. Am J Physiol 280:R1322–R1331, 2001 the rat. Clin Exp Pharmacol Physiol 28:1100–1103, 2001
30. Ballew JR, Watts SW, Fink GD: Effects of salt intake and angio- 37. Tammesild PJ, Hodgson WC, King RG: Increased sensitivity to
tensin II on vascular reactivity to endothelin-1. J Pharmacol Exp endothelin-1 in isolated Krebs’-perfused kidneys of streptozotocin-
Ther 296:345–350, 2001 diabetic rats. Clin Exp Pharmacol Physiol 19:261–265, 1992
31. Dohi Y, Hahn AW, Boulanger CM, et al: Endothelin stimulated 38. Hargrove GM, Dufresne J, Whiteside C, et al: Diabetes mellitus
by angiotensin II augments contractility of spontaneously hyper- increases endothelin-1 gene transcription in rat kidney. Kidney Int
58:1534–1545, 2000tensive rat resistance arteries. Hypertension 19:131–137, 1992
